DOP2018000057A - Composiciones biofarmacéuticas - Google Patents

Composiciones biofarmacéuticas

Info

Publication number
DOP2018000057A
DOP2018000057A DO2018000057A DO2018000057A DOP2018000057A DO P2018000057 A DOP2018000057 A DO P2018000057A DO 2018000057 A DO2018000057 A DO 2018000057A DO 2018000057 A DO2018000057 A DO 2018000057A DO P2018000057 A DOP2018000057 A DO P2018000057A
Authority
DO
Dominican Republic
Prior art keywords
compositions
biopharmaceutical compositions
biopharmaceutical
interleukin
present description
Prior art date
Application number
DO2018000057A
Other languages
English (en)
Inventor
A Monck Myrna
B Bam Narendra
Dally Jennifer
Spatara Michelle
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2018000057(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of DOP2018000057A publication Critical patent/DOP2018000057A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente descripción se refiere a composiciones, para tratar enfermedades mediadas por interleuquina 5 (IL-5), y métodos relacionados.
DO2018000057A 2015-08-24 2018-02-21 Composiciones biofarmacéuticas DOP2018000057A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562209000P 2015-08-24 2015-08-24
US201562240131P 2015-10-12 2015-10-12
US201562247906P 2015-10-29 2015-10-29
US201562249497P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
DOP2018000057A true DOP2018000057A (es) 2018-03-15

Family

ID=56877084

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000057A DOP2018000057A (es) 2015-08-24 2018-02-21 Composiciones biofarmacéuticas

Country Status (22)

Country Link
US (7) US10870695B2 (es)
EP (2) EP3341409A1 (es)
JP (3) JP6821659B2 (es)
KR (1) KR20180037275A (es)
CN (5) CN108137683A (es)
AU (1) AU2016311385C1 (es)
BR (1) BR112018003741A2 (es)
CA (1) CA2996088A1 (es)
CL (1) CL2018000499A1 (es)
CO (1) CO2018001840A2 (es)
CR (1) CR20180115A (es)
DO (1) DOP2018000057A (es)
EA (1) EA037487B1 (es)
IL (1) IL257539A (es)
MA (1) MA42692A (es)
MX (1) MX2018002319A (es)
PE (1) PE20181176A1 (es)
PH (1) PH12018500379A1 (es)
TW (2) TWI780988B (es)
UY (1) UY36868A (es)
WO (1) WO2017033121A1 (es)
ZA (1) ZA201801158B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42692A (fr) * 2015-08-24 2018-07-04 Glaxosmithkline Ip No 2 Ltd Compositions biopharmaceutiques
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3559030B1 (en) 2016-12-23 2024-04-03 Cephalon LLC Anti-il-5 antibodies
AU2018273174B2 (en) 2017-05-26 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions and related methods
JP7295038B2 (ja) * 2017-06-06 2023-06-20 グラクソスミスクライン エルエルシー 小児患者のための生物薬剤組成物及び方法
BR112020005766A2 (pt) 2017-09-29 2020-10-13 Jiangsu Hengrui Medicine Co., Ltd. anticorpo il-5, fragmento de ligação ao antígeno do mesmo, e aplicação médica do mesmo
WO2019224724A1 (en) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants
WO2020200099A1 (zh) 2019-03-29 2020-10-08 江苏恒瑞医药股份有限公司 包含抗il-5抗体的药物组合物及其用途
IL293753A (en) * 2019-12-18 2022-08-01 Tesaro Inc Biopharmaceutical preparations and related methods
AU2022349077A1 (en) * 2021-09-22 2024-03-28 Sonoma Biotherapeutics, Inc. Il5ra cell surface markers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2129445A1 (en) 1992-02-06 1993-08-07 Chuan-Chu Chou Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
WO1996021000A2 (en) 1994-12-23 1996-07-11 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
GB9712410D0 (en) 1997-06-14 1997-08-13 Glaxo Group Ltd Peptides and compounds that bind to the il-5 receptor
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
JP5528710B2 (ja) 2006-02-28 2014-06-25 オリガシス コーポレイション アクリロイルオキシエチルホスホリルコリン含有ポリマー抱合体及びその製法
EP2152310A4 (en) 2007-04-30 2010-05-26 Glaxosmithkline Llc METHODS OF ADMINISTERING ANTI-IL-5 ANTIBODIES
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
US20110008345A1 (en) * 2007-11-30 2011-01-13 Claire Ashman Antigen-binding constructs
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US9834600B2 (en) 2008-03-28 2017-12-05 Glaxosmithkline Llc Methods of treatment of eosinophilic bronchitis with an anti-IL-5 antibody
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5657224B2 (ja) 2009-08-31 2015-01-21 富士フイルム株式会社 放射線画像検出器の撮像面の設置誤差の程度を判定する方法および装置
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
WO2011087066A1 (ja) 2010-01-14 2011-07-21 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
US10286037B2 (en) 2011-02-09 2019-05-14 Glaxosmithkline Llc Methods of producing lyophilized polypeptide composition formulations comprising volatile additives
JP2014510152A (ja) 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
EA201391488A1 (ru) 2011-04-07 2014-01-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
CA2899308C (en) * 2013-03-14 2017-04-18 Abbvie Inc. Low acidic species adalimumab compositions and uses thereof
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
US20160235667A1 (en) 2013-10-02 2016-08-18 Vectura Limited Method and apparatus for making compositions for pulmonary administration
SI3097122T1 (sl) 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
KR102301188B1 (ko) 2014-02-06 2021-09-13 엑스4 파마슈티컬스 (오스트리아) 게엠베하 이. 콜라이 특이성 항체 서열
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
MA42692A (fr) 2015-08-24 2018-07-04 Glaxosmithkline Ip No 2 Ltd Compositions biopharmaceutiques

Also Published As

Publication number Publication date
US11274148B2 (en) 2022-03-15
EA037487B1 (ru) 2021-04-02
MX2018002319A (es) 2018-04-11
MA42692A (fr) 2018-07-04
US20220380452A1 (en) 2022-12-01
BR112018003741A2 (pt) 2018-09-25
PE20181176A1 (es) 2018-07-20
US10870695B2 (en) 2020-12-22
JP2018526369A (ja) 2018-09-13
US20210340247A1 (en) 2021-11-04
JP2020033351A (ja) 2020-03-05
TWI780988B (zh) 2022-10-11
US20200199219A1 (en) 2020-06-25
US20180251539A1 (en) 2018-09-06
CL2018000499A1 (es) 2018-07-06
EA201890572A1 (ru) 2018-10-31
WO2017033121A1 (en) 2017-03-02
EP3341409A1 (en) 2018-07-04
US11299541B2 (en) 2022-04-12
US20210340246A1 (en) 2021-11-04
TWI750133B (zh) 2021-12-21
US20220185878A1 (en) 2022-06-16
PH12018500379A1 (en) 2018-09-03
CN116327923A (zh) 2023-06-27
AU2016311385B2 (en) 2019-05-09
US20210332125A1 (en) 2021-10-28
TW201722473A (zh) 2017-07-01
JP7463070B2 (ja) 2024-04-08
AU2016311385C1 (en) 2019-08-22
TW202233238A (zh) 2022-09-01
UY36868A (es) 2017-03-31
CN116327922A (zh) 2023-06-27
ZA201801158B (en) 2019-08-28
CR20180115A (es) 2018-04-12
AU2016311385A1 (en) 2018-03-15
JP6821659B2 (ja) 2021-01-27
CA2996088A1 (en) 2017-03-02
KR20180037275A (ko) 2018-04-11
CN116327921A (zh) 2023-06-27
CO2018001840A2 (es) 2018-05-31
JP2022023049A (ja) 2022-02-07
CN108137683A (zh) 2018-06-08
IL257539A (en) 2018-04-30
CN116474091A (zh) 2023-07-25
EP4056590A1 (en) 2022-09-14
US11459384B2 (en) 2022-10-04
US11286298B2 (en) 2022-03-29

Similar Documents

Publication Publication Date Title
DOP2018000057A (es) Composiciones biofarmacéuticas
CL2016002455A1 (es) Anticuerpos multiespecíficos.
BR112018011089A2 (pt) composições e métodos para a imuno-oncologia
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
CO2018000648A2 (es) Compuestos de piridina sustituidos, intermediarios para su preparación y composiciones que los comprenden
BR112019012342A2 (pt) anticorpos il-11
BR112018000482A2 (pt) ?composição herbicida, utilização da composição, método para o controle da vegetação indesejada e utilização?
BR112019018124A2 (pt) composições e métodos para imunooncologia
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
BR112017013498A2 (pt) composições de inibidor de nitrificação e métodos para a preparação das mesmas
BR112016008685A2 (pt) Gene para indução de partenogênese, componente de reprodução apomítica
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
BR112016017584A2 (pt) Composições de nanotribologia e métodos relacionados incluindo nanofolhas moleculares
CL2020000869A1 (es) Enantiómeros de tiazoles sustituidos compuestos antivirales.
MX2016003892A (es) Uso de dihidrooxindolilsulfonamidas sustituidas, o sus sales, para aumentar la tolerancia de plantas al estres.
BR112017005109A2 (pt) produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário
BR112018003800A2 (pt) derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processo para a sua produção e utilização
MX2016013308A (es) Uso de oxotetrahidroquinolinilsulfonamidas sustituidas o sus sales para aumentar la tolerancia al estres en plantas.
CL2017002255A1 (es) Procesos para preparar fluorocetólidos.
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
BR112017015298A2 (pt) processo para a decomposição de material de biomassa contendo lignocelulose?
UY37763A (es) 2,5-dibromopiridina y procesos para prepararla